Every Form 4 that Exact Sciences Corp (EXAS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EXAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXAS filings page.
Exact Sciences EVP Brian Baranick reported changes in his equity as the Abbott acquisition closed. On March 23, 2026, Exact Sciences merged into a wholly owned Abbott subsidiary, with each share of Exact common stock converted into the right to receive $105.00 in cash.
At the merger’s effective time, his performance-based restricted stock units became fully vested based on actual performance levels and were cancelled for cash at $105.00 per underlying share. His outstanding restricted stock units were disposed of or converted, and his Exact common stock holdings, including shares in a 401(k) plan, were surrendered to the issuer, leaving no remaining Exact holdings reported after these transactions.
Certain restricted stock units granted on or after November 19, 2025 were assumed by Abbott as replacement restricted stock units on substantially the same terms, with the new awards vesting in four equal annual installments beginning on February 25, 2027.
Exact Sciences Corporation senior vice president and general counsel James Herriott reported the final treatment of his equity as the company was acquired by Abbott Laboratories. On the March 23, 2026 merger closing, each Exact Sciences common share was converted into the right to receive $105.00 in cash, without interest.
Herriott’s outstanding stock options were cancelled and, where the exercise price was below $105.00 per share, converted into a cash right equal to the spread over the merger price, less taxes. His Exact Sciences restricted stock units were similarly terminated as issuer awards, with RSUs granted on or after November 19, 2025 assumed by Abbott as new parent RSUs on substantially the same terms.
This Form 4 records a series of dispositions to the issuer, not open‑market trades, and reflects that Herriott no longer holds Exact Sciences equity following the merger, with his continuing equity exposure now in Abbott equity-based awards.
EXACT SCIENCES CORP EVP and Chief Financial Officer Aaron Bloomer reported a series of equity changes tied to the company’s merger with Abbott Laboratories. At the merger’s effective time, each share of Exact common stock and each vested equity unit was converted into the right to receive $105.00 in cash per share, less applicable taxes.
The filing shows performance-based and time-based restricted stock units being fully vested, cancelled, and exchanged for this cash consideration, while certain newer RSUs were assumed as Abbott restricted stock units on substantially the same terms. Following these transactions, the Form 4 indicates no remaining Exact Sciences common stock or RSU holdings for Bloomer.
Exact Sciences EVP of Human Resources Sarah Condella reported a series of equity adjustments tied to the completion of the company’s merger with Abbott Laboratories. On March 23, 2026, Badger Merger Sub I merged into Exact Sciences, making Exact a wholly owned subsidiary of Abbott.
At the effective time of the merger, each share of Exact common stock outstanding was converted into the right to receive $105.00 in cash per share. Performance-based restricted stock units became fully vested based on achievement levels as of November 19, 2025 and were cancelled for the same $105.00 per-share cash consideration, less applicable tax withholding.
Stock options with exercise prices below $105.00 were cancelled and converted into cash equal to the spread between $105.00 and the option exercise price, multiplied by the number of underlying shares. Restricted stock units granted on or after November 19, 2025 were assumed by Abbott as Abbott restricted stock units on substantially the same terms.
Exact Sciences Corporation completed its merger with a subsidiary of Abbott Laboratories on March 23, 2026, with Exact Sciences becoming a wholly owned Abbott subsidiary. At the merger’s effective time, each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash per share, subject to tax withholding.
For President and CEO Kevin T. Conroy, all reported stock options and restricted stock units were cancelled and treated in cash or converted into Abbott equity under the merger agreement. In-the-money options were cancelled for a cash payment based on the $105.00 merger consideration minus the option exercise price, while performance-based and time-based RSUs were either fully vested and paid in cash or assumed as Abbott restricted stock units. Following these transactions, the filing shows no remaining Exact Sciences common stock or derivatives reported for Conroy.
EXACT SCIENCES CORP EVP and GM of Screening Jacob A. Orville reported merger-related equity changes tied to the company’s acquisition by Abbott Laboratories. In the merger, each share of common stock was converted into the right to receive $105.00 in cash.
On March 23, 2026, the executive disposed of stock options, restricted stock units, and common shares (including 401(k) holdings) back to the issuer as part of the transaction and received a grant of 53,323 shares of common stock as a compensation award. The new award vests in four equal annual installments beginning on February 25, 2027.
Exact Sciences Corporation director D. Scott Coward reported the cancellation and disposition of his equity in connection with the company’s merger with Abbott Laboratories. At the merger’s effective time, each Exact Sciences common share was converted into the right to receive $105.00 in cash, without interest. Coward’s restricted and other common shares, including shares held in a 401(k) plan, were deemed fully vested, cancelled, and converted into the cash merger consideration, subject to tax withholding. His outstanding stock options with exercise prices below $105.00 were cancelled and converted into cash equal to the spread between $105.00 and the option exercise price, multiplied by the underlying shares. Following these issuer dispositions, the Form 4 shows he no longer holds Exact Sciences common stock or related stock options.
Exact Sciences director Shacey Petrovic reported disposing of all common stock holdings in connection with the closing of Exact Sciences’ merger with Abbott Laboratories. The Form 4 shows issuer dispositions of 16,406 and 5,398 directly held shares, plus 7,095 shares held indirectly in a grantor retained annuity trust.
According to the merger terms, at the effective time each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares outstanding immediately before the merger became fully vested, were cancelled, and likewise converted into the cash merger consideration (less any applicable tax withholding).
EXACT Sciences Corp director Katherine S. Zanotti reported disposing of all her common stock in connection with the company’s acquisition by Abbott Laboratories. On March 23, 2026, Badger Merger Sub I, Inc. merged with Exact Sciences, leaving Exact as a wholly owned Abbott subsidiary.
At the merger’s effective time, each outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. Zanotti’s 55,361 shares, plus an additional 5,398 shares, were cancelled and converted into the cash merger consideration, leaving her with no remaining Exact Sciences holdings. All restricted shares under company plans became fully vested and were also converted into the same cash amount per share, net of any tax withholding.
EXACT SCIENCES CORP director Kimberly J. Popovits reported the disposition of her remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, Exact Sciences became a wholly owned subsidiary of Abbott under a previously signed merger agreement.
At the effective time of the merger, each outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares subject to vesting or other restrictions were deemed fully vested, cancelled, and similarly converted into the cash merger consideration, leaving Popovits with no remaining Exact Sciences common stock.
Exact Sciences Corp director James Edward Doyle reported disposing of his remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, 52,564 shares of Exact Sciences common stock were returned to the issuer, leaving 5,398 shares. A second disposition of 5,398 shares reduced his direct holdings to zero. Under the merger agreement, each Exact Sciences share outstanding at the effective time was converted into the right to receive $105.00 in cash, and restricted shares became fully vested and cancelled for the same cash consideration, less applicable tax withholding.
Exact Sciences director Paul J. Clancy disposed of his common stock in connection with the company’s cash merger with Abbott Laboratories. On March 23, 2026, he reported issuer dispositions totaling 26,038 shares of common stock, leaving him with zero shares after the transactions.
Under the merger agreement, each Exact Sciences share outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Shares of common stock that were subject to vesting or other restrictions under company stock plans were deemed fully vested at the effective time, then cancelled and converted into the same cash merger consideration, less any applicable tax withholding.
Exact Sciences Corporation director Michael J. Barber reported disposing of all his company equity in connection with the closing of a cash merger with Abbott Laboratories. At the merger’s effective time, each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest, under the Merger Agreement.
All restricted common stock and each deferred stock unit became fully vested, then were cancelled and converted into the right to receive the same $105.00 cash consideration per underlying share, less applicable tax withholding. Barber’s Form 4 shows issuer dispositions of deferred stock units and common stock, leaving him with no remaining Exact Sciences shares or deferred stock units.
EXACT SCIENCES CORP director Leslie Trigg disposed of all her directly held common shares back to the company in connection with its cash merger with Abbott Laboratories. One transaction returned 3,244 shares and a second returned 13,925 shares, leaving her with zero shares afterward.
Under the merger terms, each Exact Sciences common share outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Stock awards subject to vesting or other restrictions were also deemed fully vested, cancelled and converted into the same cash consideration, less applicable tax withholding.
Exact Sciences President and CEO Kevin T. Conroy reported multiple equity compensation events involving restricted stock units and common stock. On February 27, 2026, several restricted stock unit awards vested, each unit representing a right to receive one share of common stock.
Upon vesting, Mr. Conroy acquired corresponding shares of common stock through derivative exercises, and the company retained blocks of 8,528, 10,419, and 13,060 shares at $103.25 per share for tax withholding purposes. After these transactions, he directly held 1,278,045 shares in various accounts and plans, plus additional indirect holdings.
A footnote states that, in addition to the common shares reported, Mr. Conroy also holds an aggregate of 737,129 vested and unvested options and restricted stock units, each unit representing a contingent right to receive one share of common stock.
Exact Sciences EVP of Human Resources Sarah Condella reported several equity transactions in company stock. She exercised stock options covering 3,900 shares of Common Stock at an exercise price of $5.03 per share, increasing her direct holdings before related tax withholding.
To cover tax obligations from this option exercise, 1,913 shares of Common Stock were retained by Exact Sciences at $103.38 per share, leaving her with 131,121 shares held directly and 6,368 shares held indirectly in a 401(k) plan. Footnotes note that the Form 4 covers 137,489 shares of Common Stock in total and that she also holds an additional 71,243 vested and unvested options and restricted stock units.
Condella Sarah reported acquisition or exercise transactions in this Form 4 filing.
EXACT Sciences executive Sarah Condella received an equity award in the form of restricted stock units. On February 25, 2026, the EVP of Human Resources was granted 23,224 restricted stock units at a price of $0.00 per unit.
Each restricted stock unit represents a contingent right to receive one share of common stock and will vest in four equal annual installments beginning on February 25, 2027. After this award, she holds 135,489 shares of common stock (including 129,134 shares held directly and 6,355 shares held indirectly in a 401(k) plan), and in addition holds 75,143 vested and unvested options and restricted stock units.
Herriott James reported acquisition or exercise transactions in this Form 4 filing.
Exact Sciences Corp reported that SVP, General Counsel & Secretary James Herriott received a grant of 20,321 restricted stock units (RSUs) on February 25, 2026. Each RSU represents a contingent right to receive one share of common stock and carries no purchase price.
These RSUs vest in four equal annual installments beginning on February 25, 2027. After this award, Herriott holds a total of 69,577 shares of common stock (including shares held directly and in a 401(k) plan), and in addition holds an aggregate of 23,975 vested and unvested options and restricted stock units tied to Exact Sciences common stock.
EXACT SCIENCES CORP President and CEO Kevin T. Conroy reported multiple equity compensation transactions. On February 25, 2026, he was granted 154,829 restricted stock units, each representing a contingent right to receive one share of common stock, and received an additional 13,181 shares of common stock upon vesting of a restricted stock unit award.
On the same date, 6,196 shares of common stock were disposed of at $103.45 per share to satisfy tax withholding obligations in connection with the net-settlement of vested restricted stock units. A related footnote states these restricted stock units vest in four equal annual installments beginning on February 25, 2027. The filing also notes that, beyond the 1,521,721 shares of common stock reported, Mr. Conroy holds an additional 805,226 vested and unvested options and restricted stock units.
Baranick Brian reported acquisition or exercise transactions in this Form 4 filing.
EXACT SCIENCES CORP executive Brian Baranick received an equity award in the form of restricted stock units. On February 25, 2026, he was granted 28,063 restricted stock units, each representing a contingent right to receive one share of common stock at no purchase price.
These restricted stock units vest in four equal annual installments beginning on February 25, 2027, tying the award to multi‑year service. Following this grant, Baranick holds 103,874 shares of common stock directly, 795 shares indirectly through a 401(k) plan, and in aggregate an additional 28,063 restricted stock units.
ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.
EXACT SCIENCES CORP EVP Jacob A. Orville received an equity award of 38,707 restricted stock units on February 25, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in four equal annual installments beginning on February 25, 2027.
After this grant, Mr. Orville directly holds 100,403 shares of common stock and indirectly holds 1,759 shares through a 401(k) plan, for a total of 102,162 shares reported. He also holds, in the aggregate, an additional 45,288 vested and unvested options and restricted stock units.
Bloomer Aaron reported acquisition or exercise transactions in this Form 4 filing.
Exact Sciences EVP and CFO Aaron Bloomer received an equity award of 28,063 restricted stock units. Each unit represents a contingent right to receive one share of common stock at no purchase price.
These restricted stock units vest in four equal annual installments beginning on February 25, 2027. After this award, Bloomer directly holds 48,768 shares of common stock and an additional 417 shares are held indirectly in a 401(k) plan, totaling 49,185 shares. He also holds, in the aggregate, 32,458 restricted stock units.
EXACT Sciences Corp. (EXAS) executive vice president and general manager of Screening, Jacob A. Orville, reported an open‑market sale of company stock. On 11/19/2025, he sold 5,000 shares of EXAS common stock at a price of $75 per share in a transaction coded "S" for sale.
After this transaction, Orville beneficially owns 23,237 shares of common stock directly and 1,490 shares indirectly through a 401(k) plan, for a total of 24,727 common shares. In addition, he holds an aggregate of 79,661 vested and unvested stock options and restricted stock units, each RSU representing a contingent right to receive one share of common stock.
The filing notes that the reported sale was carried out under a Rule 10b5‑1 trading plan that Orville entered into on May 27, 2025, indicating the trade was made pursuant to a pre‑arranged plan.
Exact Sciences Corp. executive James Herriott, SVP, General Counsel & Secretary, reported selling 1,000 shares of the company’s common stock on 11/19/2025 at a price of $70 per share under a pre-arranged Rule 10b5-1 trading plan entered into on March 3, 2025. After this sale, he beneficially owns 11,585 shares directly and 1,556 shares held in a 401(k) plan, for a total of 13,141 shares. In addition, he holds an aggregate of 37,434 vested and unvested stock options and restricted stock units, each unit representing the right to receive one share of common stock.
Exact Sciences (EXAS) executive James Herriott, SVP, General Counsel & Secretary, reported the sale of 1,500 shares of common stock at $70.08 on 11/04/2025. The transaction was made under a Rule 10b5-1 trading plan entered on March 3, 2025.
After the sale, Herriott beneficially owned 12,585 shares directly and 1,556 shares held indirectly in a 401(k) plan. He also holds an aggregate 37,434 vested and unvested options and restricted stock units.
Exact Sciences (EXAS) reported an insider transaction by EVP, GM, Precision Oncology Brian Baranick. He sold 2,858 shares of common stock on 11/04/2025 at $70.08 per share, executed pursuant to a Rule 10b5-1 trading plan entered into on May 13, 2024.
Following the sale, he beneficially owned 22,368 shares directly and 670 shares held in a 401(k) plan. In addition, he holds an aggregate of 73,080 vested and unvested options and restricted stock units, with each RSU representing a contingent right to receive one share of common stock.
Exact Sciences (EXAS) reported an insider transaction: a director sold shares in an open-market trade. On 10/24/2025, the reporting person sold 12,000 shares of common stock at $65 per share under a pre-arranged Rule 10b5-1 trading plan entered on 11/25/2024. Following the sale, the individual beneficially owns 60,759 shares, held directly.
Insider transaction summary: An officer of Exact Sciences Corporation sold 1,500 shares of common stock on 10/09/2025 at a price of $60 per share, leaving beneficial ownership of 14,085 shares reported on this form. The sale was executed under a written Rule 10b5-1 trading plan entered into on 03/03/2025, which the filer checked as applicable. In addition to the reported shares, the reporting person holds an aggregate 37,434 vested and unvested equity awards (options and restricted stock units), each restricted stock unit representing a contingent right to one share. The Form 4 was signed by an attorney-in-fact on 10/10/2025.
Director sale under 10b5-1 plan: A director of Exact Sciences Corp. (EXAS) sold 2,000 shares of common stock on 10/09/2025 at a price of $60 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the transaction the reporting person beneficially owned 57,962 shares. The sale was reported on a Form 4 executed by an attorney-in-fact. This filing discloses a single routine disposition by an insider using a pre-established plan and does not include other derivative or non-derivative transactions.